Drug reimbursement up 4.5% y-o-y in January-July 2018

The National Health Fund (NFZ) spent PLN 7.1bn (€1.7bn) on drug reimbursement in the first seven months of 2018, an increase of 4.5% compared with the same period of 2017. The amount represents 57% of the NFZ’s projected drug reimbursement spend in 2018 as a whole.

Of the total sum spent by the NFZ in January-July 2018, spending on the reimbursement of products available upon prescription in the pharmacy channel – medicines, foods for particular nutritional uses, and medical devices – amounted to PLN 4.9bn (€1.2bn), an increase of 3.5%. The figure represents 59% of the annual plan.

Reimbursement of hospital drugs via drug programmes amounted to PLN 1.78bn (€414m) and was 6.5% higher than a year ago. The amount represents 53.1% of the full-year plan.

Reimbursement of chemotherapy drugs slightly exceeded PLN 372m (€87m) in January-July 2018, up 8% year on year. The amount represents 54.2% of the annual plan.

NFZ spending on drug reimbursement (PLN m), change (%, y-o-y) and its share (%) in planned annual budget (PLN m), Jan-Jul 2018
PMR based on NFZ, 2018
Specification Jan-Jul 2017 Jan-Jul 2018 Change Planned budget for 2018 Spending in Jan-Jul 2018 as a percentage of planned budget
Medicines, foods for particular nutritional uses and medical devices available upon prescription in the pharmacy channel 4,759.9 4,926.6 3.5% 8,375.3 58.8%
Reimbursement via drug programmes 1,668.9 1,776.9 6.5% 3,348.9 53.1%
Chemotherapy drugs 343.9 372.4 8.3% 687.1 54.2%
Other 12.4 14.0 12.8% 36.5 38.4%
Total 6,785.2 7,089.9 4.5% 12,447.8 57.0%